Association Between Benzodiazepine Use in Early Pregnancy, Miscarriage Risk

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 15, 2019

Media advisory: To contact corresponding author Anick Berard, Ph.D., email Florence Meney at Florence.Meney.hsj@ssss.gouv.qc.ca. The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article: This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2733517?guestAccessKey=b19138a8-8ac9-4d51-be62-6e52aaa3fa9b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051519

 

Bottom Line: Benzodiazepines are a class of drugs used to treat anxiety, insomnia and mood disorders. This observational study examined the risk of miscarriage associated with their use in early pregnancy by drug class, specific agent and short- or long-acting formulation in about 442,000 pregnancies in Canada from 1998 through 2015. Among the pregnancies, 27,000 (6.1%) ended in miscarriage and 1.4% of those miscarriages were among women who used benzodiazepines in early pregnancy. The study reports any benzodiazepine use during early pregnancy was associated with increased risk of miscarriage. A limitation of the study is its lack of information on alcohol use by the women, which could have influenced the results. These findings suggest physicians should carefully evaluate the risks and benefits of prescribing benzodiazepines in early pregnancy since alternative treatments exist.

Authors: Anick Berard, Ph.D., Centre Hospitalier Universitaire Sainte-Justine, Montreal, and coauthors

 

(doi:10.1001/jamapsychiatry.2019.0963)

Editor’s Note: The article contains conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.